About Celgene

Celgene is committed to improving the lives of patients worldwide by developing innovative therapies that are helping to turn incurable blood cancers into chronic, manageable diseases. Its mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

There are numerous clinical trials at major medical centers using approved and investigational compounds from Celgene. These disease-altering therapies are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.